M3, Inc. (MTHRY)
OTCMKTS · Delayed Price · Currency is USD
7.98
+0.13 (1.66%)
Sep 17, 2025, 2:22 PM EDT
M3, Inc. Revenue
M3, Inc. had revenue of 86.20B JPY in the quarter ending June 30, 2025, with 34.25% growth. This brings the company's revenue in the last twelve months to 306.89B, up 24.91% year-over-year. In the fiscal year ending March 31, 2025, M3, Inc. had annual revenue of 284.90B with 19.26% growth.
Revenue (ttm)
306.89B JPY
Revenue Growth
+24.91%
P/S Ratio
5.13
Revenue / Employee
19.98M JPY
Employees
15,360
Market Cap
10.92B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 284.90B | 46.02B | 19.26% |
| Mar 31, 2024 | 238.88B | 8.07B | 3.49% |
| Mar 31, 2023 | 230.82B | 22.66B | 10.89% |
| Mar 31, 2022 | 208.16B | 38.96B | 23.03% |
| Mar 31, 2021 | 169.20B | 38.23B | 29.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 2.12M |
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| AMJ Global Technology | 39.00 |
M3, Inc. News
- 4 years ago - M3, Inc.: Stand-Out Success Story Of Japanese Internet - Seeking Alpha
- 4 years ago - 5 Health Care Stocks Growing Fast - GuruFocus
- 5 years ago - 5 Telehealth Stocks for Long-Term Financial Fitness - Kiplinger